AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 77 | |
4 mg | In stock | $ 138 | |
8 mg | In stock | $ 204 | |
20 mg | In stock | $ 347 | |
40 mg | In stock | $ 551 |
Description | AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2. |
Targets&IC50 | PI3Kδ:18 nM |
In vitro | AMG319 inhibits anti-IgM/CD40L-induced B cell proliferation with IC50 of 8.6 nM and reduces pAkt level with IC50 of 1.5 nM. AMG319 also inhibits anti-IgD-induce CD-69 expression in HWB. |
In vivo | In female Lewis rats, AMG319 (3 mg/kg, p.o.) inhibits the KLH-induced inflammatory response by 88%. In the transgenic (IgMm) mice, AMG319 (, p.o.) inhibits in vivo pAKT with IC50 of 1.9 nM. |
CAS No. | 1608125-21-8 |
Chemical Formula | C21H16FN7 |
Molecular Weight | 385.406 |
Solubility | H2O: <1 mg/mL DMSO: 71 mg/mL (184.2 mM); Ethanol: 71 mg/mL (184.2 mM) |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom